Iroko names Louis Vollmer president, CEO
PHILADELPHIA — Iroko Pharmaceuticals on Monday announced that it had named Louis Vollmer to the positions of president and CEO at the company, effective July 6. He has been president of the company since March 2015 and succeeds Iroko founder Osagie Imasogie as CEO.
Vollmer will oversee day-to-day operations and long-term planning for Iroko, with a focus on its SoluMatrix franchise brands. Osagie will stay on as chairman of Iroko’s board.
"Lou is a seasoned and well-respected leader whose perspective and business acumen will be invaluable to Iroko as it evolves into a true leader in providing responsible pain management options to healthcare professionals and patients," Imasogie said.
Vollmer began his more than 25-year career in the pharmaceutical industry at DuPont Merck, eventually becoming SVP sales and marketing for DuPont Multi Source Products. He was also one of three founding partners and management team leaders of Endo Pharmaceuticals.
“I am honored to lead Iroko at this stage of the company's evolution," Vollmer said. “Iroko is in a strong position for growth within the United States and worldwide. I look forward to helping the company deliver significant value to patients and healthcare professionals and achieving strong and sustainable growth.”
FDA approves new Xolair indication
SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Xolair (omalizumab), Genentech and Novartis, which work together to develop and co-promote the drug in the U.S., announced.
Xolair can now be used in patients 6 to 11 years of age with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to airborne allergens and whose symptoms are controlled adequately by corticosteroids. The drug had previously been approved to treat allergic asthma in patients 12 years of age and older.
“Despite our best efforts to control symptoms with inhaled corticosteroids and other medicines, allergic asthma remains a serious problem for many children,” Genentech chief medical officer and head of global product development Dr. Sandra Horning said. “With this approval, we’re pleased to see a proven treatment option is now available for appropriate patients six and older.”
Fred’s provided more than 100K screening touch points in Q1
MEMPHIS, Tenn. — Fred’s Pharmacy on Thursday announced that from February to April this year, the company provided more than 100,000 preventative screening touch points to its patients. These touch points included more than 60,000 kits to screen for colorectal cancer, almost 37,000 blood pressure screenings and almost 800 flu shots.
“For many of our customers, the most frequent interaction they have with a health care provider is with Fred’s more than 1,000 Pharmacists,” Fred’s director pharmacy operations Jaime O’Bar said. “The first step in preventing disease and improving health is personal awareness, and we are honored that our customers trust Fred’s Pharmacists in a way that has had a direct impact on their health.”
According to the Centers for Disease Control and Prevention, colorectal cancer caused more than 134,000 deaths in 2012, heart disease causes more than 370,000 deaths each year and flu viruses cause some 36,000 deaths.
Fred’s said that it offers year-round immunizations for the flu, measles, shingles and pneumonia, among others, in addition to its medication synchronization program and 90-day prescription services.
Loading Post Please Wait...